Chemistry:GM-3009
GM-3009 is a κ-opioid receptor (KOR) agonist and noribogaine analogue which is under development for the treatment of opioid-related disorders.[1][2][3] Its route of administration is unspecified.[1] The drug is a highly potent agonist of the human KOR, with an affinity (Ki) of 0.9 nM or 87.3 nM depending on the radioligand and an EC50 of 0.8 nM.[3] In contrast to noribogaine, it did not show pro-arrhythmic effects in fresh human ventricular cardiomyocytes ex vivo.[3] GM-3009 produces antinociceptive effects and dose-dependently reduces oxycodone self-administration in rodents.[3] It is being developed by Gilgamesh Pharmaceuticals.[1][2] As of June 2024, it is in the preclinical research stage of development.[1][2] The exact chemical structure of GM-3009 does not yet appear to have been disclosed.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "GM 3009". 19 June 2024. https://adisinsight.springer.com/drugs/800077750.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on GM-3009 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/73f39db6d983477c95dd040cb74052d2.
- ↑ 3.0 3.1 3.2 3.3 "ACNP 62nd Annual Meeting: Poster Abstracts P501 – P753: P720. GM-3009 is a Novel Noribogaine Analog That Disrupts Opioid Self-Administration in Rats Via Agonism of Kappa Opioid Receptors Without Pro-Arrhythmic Effects on Human Cardiomyocytes". Neuropsychopharmacology 48 (S1): 355–495 (478–478). 2023. doi:10.1038/s41386-023-01757-3. ISSN 0893-133X. PMID 38040811. PMC 10729598. https://www.nature.com/articles/s41386-023-01757-3.pdf. Retrieved 16 February 2025.
 |  |
